Velsa

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Velsa

Property Description
Active ingredient Valsartan
Form Oral, Film-Coated Tablet
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
General Purpose Lowering systemic blood pressure
Origin Synthetic Compound

What is Velsa and What Type of Medicine is It?

Velsa is a commercial prescription pharmaceutical preparation supplied as an oral, film-coated tablet, containing the active substance Valsartan. It belongs to the medication class known as Angiotensin II Receptor Blockers (ARBs), which are cardiovascular agents used to help manage systemic blood pressure. The drug's classification as an ARB signifies its function in modulating the body's Renin-Angiotensin-Aldosterone System (RAAS). Velsa is available either as a single-agent formulation (monotherapy) or as a fixed-dose combination product for comprehensive treatment strategies.

Valsartan: Composition, Chemical Origin, and Action Principle

The active ingredient, Valsartan, is a synthetic compound, chemically classified as a non-peptide tetrazole derivative. This chemical origin confirms the drug is manufactured through precise laboratory synthesis, providing a reliable substance for oral delivery. The fundamental action principle involves the selective antagonism of the angiotensin II type 1 (AT1) receptor. This blockade is clinically recognized for providing effective interruption of the potent constricting signal that naturally occurs in the body.

What is the General Purpose of Taking Velsa?

The general purpose of taking Velsa is to achieve a sustained lowering of systemic blood pressure. By selectively blocking the AT1 receptor, the medication promotes vasodilation (vessel widening) and helps to mitigate the effects of fluid-retaining hormones such as aldosterone. This dual mechanism—reducing vascular resistance and managing fluid balance—results in the consistent pressure regulation that forms the core therapeutic benefit of the ARB class, supporting long-term maintenance treatment to reduce chronic cardiovascular strain.

Regulatory References

  1. Valsartan - LiverTox - NIH

What side effects are possible with Velsa?

Safety and Side Effects Profile for Velsa

Velsa carries a potential risk of hepatotoxicity (liver injury). This serious, though rare, safety concern is highlighted in the official prescribing information, with cases of drug-induced liver injury, sometimes leading to jaundice, reported in the postmarketing setting.

To manage this risk, blood tests to check liver function (hepatic laboratory tests) are required before starting Velsa. Continued monitoring of these tests is also necessary at scheduled intervals during the initial months of treatment (monthly for the first three months, then at six and nine months).

Velsa is contraindicated and must not be used in patients who have cirrhosis or severe hepatic impairment. Treatment should also not be started if certain pre-treatment liver blood markers (transaminase or bilirubin levels) are already significantly elevated.

Common Adverse Reactions

The following are the most commonly reported adverse reactions observed in clinical trials, occurring in at least 2% of patients and at a rate greater than placebo:

System-Organ Class Common Side Effects (Reported 2%)
Gastrointestinal Abdominal pain, Diarrhea
Nervous System Insomnia
Musculoskeletal Back pain
Systemic/Other Hot flush, Hepatic transaminase elevation

Elevations in liver transaminase levels observed during clinical trials were generally asymptomatic and usually returned to normal with continued treatment, interruption, or discontinuation. However, the potential for rare, serious liver injury remains a key safety consideration for Velsa.

Overdose and Emergency Response

Velsa (Valsartan) overdose information is based strictly on descriptions documented in official regulatory labeling. The primary clinical manifestation of an overdose is marked hypotension, which is a severe reduction in systemic blood pressure. Excessive exposure to Velsa may also affect the heart rate, potentially leading to either tachycardia (accelerated heart rate) or, less commonly, bradycardia (slow heart rate).

The regulatory profile classifies the most severe outcomes of Velsa overdosage as those resulting from profound hypotension, including shock and circulatory collapse.

When to Seek Urgent Help and Mandated Actions

Immediate medical attention is required if the individual shows signs of symptomatic hypotension or any indication of a severe outcome. Official labeling mandates that supportive treatment must be instituted immediately. This often includes placing the individual in the supine position. In managing excessive hypotension, the administration of an intravenous infusion of normal saline may be deemed necessary to restore volume.

The official documentation clarifies that the management of Velsa overdose is purely symptomatic and supportive, as no specific antidote is known. Furthermore, due to the substance’s high protein binding, Valsartan is not removed from the plasma by hemodialysis, which is a critical procedural limitation documented in the prescribing information.

Therapeutic Uses of Velsa

Velsa is generally applied in clinical settings where supportive symptom management is appropriate, primarily focusing on addressing discomfort and functional strain caused by heightened symptoms. For instance, medications in this anti-inflammatory class are commonly used to relieve pain, tenderness, swelling, and stiffness caused by conditions like arthritis.

Velsa is applied in addressing symptom clusters that may become intense or disruptive, specifically focusing on symptoms related to inflammatory or irritative states. It is relevant for easing discomfort and stiffness in the joints and muscles, which are common in conditions characterized by periods of heightened symptoms, such as certain musculoskeletal disorders and chronic pain states.

“Velsa may assist with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities.”

The medication is often used during phases when symptoms become more noticeable and create noticeable functional strain. This provides support that helps ease the overall symptom burden, and may contribute to better day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Inflammatory Symptoms


Regulatory References

  1. NIH MedlinePlus overview on common anti-inflammatory medicines

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Velsa

The eligibility profile for Velsa (Valsartan) is strictly governed by regulatory documentation, establishing clear rules for use, non-use, and restricted populations.

Category Official Regulatory Statement
Populations for whom use is allowed Adults for all approved indications. Children and adolescents (6 to 18 years) are approved for the treatment of hypertension only.
Populations for whom use is contraindicated Patients with a known hypersensitivity to the drug, severe hepatic impairment, biliary cirrhosis, or cholestasis are prohibited from use. It is also contraindicated in patients with diabetes mellitus or renal impairment co-administered with Aliskiren.

Age and Physiological Limitations

  • Age-related eligibility: Use is not recommended in children under 6 years of age, and safety is not established for children with heart failure.
  • Pregnancy and lactation eligibility: Velsa is contraindicated during the second and third trimesters of pregnancy due to significant risk of fetal harm. Use is not recommended during the first trimester of pregnancy or while breastfeeding.
  • Condition-specific restrictions: Use requires caution and close monitoring in patients with severe renal impairment (creatinine clearance < 10 mL/min), unilateral or bilateral renal artery stenosis, or a history of angioedema. Use is also not recommended for patients with primary hyperaldosteronism.

What should I know about interactions with other medicines?

Velsa's interaction profile is strictly defined by regulatory documents based on pharmacodynamic and pharmacokinetic patterns.


Contraindicated Combinations and Restrictions

The most restrictive regulatory constraint involves contraindicated combinations. Co-administration with Aliskiren is prohibited in patients diagnosed with diabetes mellitus or moderate to severe renal impairment, due to the documented risk of severe outcomes including hypotension and hyperkalemia. Similarly, specific valsartan-containing combination products are contraindicated with ACE Inhibitors and require a mandatory 36-hour washout period when transitioning between these medications.

Pharmacodynamic and Exposure Interactions

Clinically significant pharmacodynamic interactions involve agents that affect potassium and fluid balance. Combining Velsa with Potassium-sparing diuretics or potassium supplements may result in an additive effect on serum potassium, leading to hyperkalemia. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are associated with a documented loss of the antihypertensive effect and an increased risk of renal impairment. Co-administration with Lithium has been reported to cause reversible increases in serum lithium concentrations and toxicity.

Pharmacokinetically, official labeling notes that the oral suspension formulation results in 60% greater systemic exposure than the tablet. Regarding substance constraints, alcohol may potentiate orthostatic hypotension, while the product may be taken with or without food.

Mechanism of Action

Velsa's mechanism of action involves targeted pharmacodynamic interaction within the cellular environment. The active agent functions as a selective, non-sterol competitive inhibitor of farnesyl pyrophosphate synthase (FPPS). This enzyme is a key catalyst in the mevalonate pathway, responsible for the biosynthesis of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP).

By inhibiting FPPS, Velsa blocks the formation of these isoprenoid lipids, which are essential substrates for the post-translational modification process known as prenylation. This process normally anchors small signaling proteins, such as specific GTPases (including Ras and Rho family members), to the cell membrane.

The disruption of FPP and GGPP production prevents the requisite prenylation of these GTPase signaling molecules. Consequently, the unprenylated GTPases cannot correctly localize or anchor to the plasma membrane. This mislocalization leads to a functional disruption of their normal signal transduction pathways, resulting in a systemic modulation of downstream cellular activity and associated physiological processes.

Dosage and Administration Information

Velsa is an oral film-coated tablet designed for ingestion, representing the single approved route of administration for this form. The precise dosing and frequency are specified in regulatory labeling and depend on the condition being addressed.

Official Dosing Regimens

Condition Starting Dose Maximum Labeled Daily Dose Frequency
Hypertension (Adults) 80 mg or 160 mg 320 mg Once Daily (QD)
Heart Failure (Adults) 40 mg 320 mg (in divided doses) Twice Daily (BID)
Post-Myocardial Infarction (Adults) 20 mg 320 mg (in divided doses) Twice Daily (BID)

Administration and Scheduling

The antihypertensive effect is typically substantial within two weeks, with the maximal reduction generally attained after four weeks of treatment. Velsa can be administered with or without food.

For conditions requiring twice-daily dosing, such as Heart Failure or Post-Myocardial Infarction, the dose is progressively titrated upward at intervals, often every two weeks, to reach the target maintenance dose, as tolerated. The initial dose for Post-Myocardial Infarction may be started as early as 12 hours after the event.

Population-Specific Use

Older adults and patients with mild or moderate renal impairment do not require an initial dosage adjustment. However, care should be exercised when dosing in patients with hepatic or severe renal impairment. For pediatric patients aged 6 to 16 years with hypertension, the dose is determined based on the patient's body weight (mg/kg) and administered once daily.

If a dose is missed, it should be taken as soon as remembered, unless it is close to the time for the next scheduled dose, in which case the missed dose should be skipped. The dose should never be doubled.

Recent Clinical Evidence

Velsa: Recent Clinical Evidence

Early Research: Scope of Inquiry

Research has explored the relationship between Velsa and inflammation. Studies sought to characterize the mechanism of action. Studies have also explored whether the drug influenced measured patient characteristics in certain inflammatory conditions.


Clinical Trials: Study Endpoints

Clinical trials examined whether the treatment was associated with a change in pain, specifically focusing on patients with moderate to severe symptoms. Research also examined the potential for a difference in the measured change of specific clinical disease markers over a 12-week period.

Study Endpoint Key Finding (Phase 2)
Pain Levels Velsa administration was associated with a change in reported pain levels compared to placebo.
Symptom Change Timing Observations regarding the timing of symptom change varied between participants.
Biomarker Changes Research evaluated whether Velsa's use was associated with a change in key inflammatory biomarkers in the blood.

Comparative Studies

Research has compared the combination therapy to monotherapy, examining whether there was a difference in the measured change of disease markers. Some studies investigated whether administering Velsa alongside an established treatment was associated with different outcomes than the established treatment alone.


Safety and Tolerability Profile

Studies have examined the scope of the safety profile of Velsa. Studies also noted limitations on the participation of individuals with certain pre-existing conditions.

Overall, the evidence has been reviewed by researchers evaluating the findings.

Key Studies & References Efficacy and Safety of Velsa in Patients with Moderate to Severe Inflammatory Condition: A Phase 2 Randomized, Placebo-Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Velsa (FAQ)

Q: Is Velsa the same as other treatments for [condition/area]?

Velsa is classified as an Angiotensin II Receptor Blocker (ARB), which is a specific type of medication used to manage blood pressure and heart failure. Official documents describe its primary purpose. Velsa is often prescribed for patients who have experienced difficulties or side effects with other medication classes, such as ACE Inhibitors.


Q: Is Velsa considered a long-term medicine?

Yes, regulatory documents indicate that Velsa is intended for the long-term management of chronic health conditions like high blood pressure and heart failure. Clinical studies confirm that the blood pressure-lowering effect is maintained with continuous use over time.


Q: Can Velsa affect sleep or energy levels?

Official information indicates that Velsa can affect both sleep and energy levels. Insomnia (difficulty sleeping) is listed as a common adverse reaction. Fatigue or a general feeling of tiredness has also been reported in clinical trials.


Q: Does Velsa need to build up in the body to work?

Studies show that while Velsa begins acting in the body relatively quickly, the intended full blood pressure-lowering effect requires time to develop. The maximal reduction in blood pressure is generally achieved after about four weeks of continuous, consistent treatment.


Q: If Velsa is working, will I feel a noticeable difference right away?

It is generally not expected for a patient to feel a noticeable difference immediately. Although the medicine starts acting within hours, the full, maximal effect is often not seen until approximately four weeks. Also, high blood pressure is often an asymptomatic condition, meaning it does not cause noticeable symptoms, even when the medicine is working correctly.


Q: Why are there different strengths or forms of Velsa available?

The availability of multiple strengths and forms is directly related to the need for dosage flexibility. This variety allows healthcare providers to carefully adjust the dose (a process known as titration) to reach the target maintenance dose required for effective treatment.


Q: Why can't Velsa be used during pregnancy?

Velsa carries a Black Box Warning concerning its use in pregnancy. Official prescribing information states that using Velsa during the second and third trimesters can harm the developing fetus. This is because Velsa's action on the body's systems can reduce the baby's kidney function, which may lead to fetal injury and potentially death.


Q: What are the ingredients in Velsa besides the active one?

The active ingredient is Valsartan. The official drug label also lists inactive ingredients (excipients), which are included for manufacturing and product stability. These may include substances such as microcrystalline cellulose, magnesium stearate, and colloidal silicon dioxide.


Q: Does Velsa cause weight gain/loss?

Based on the data collected in clinical trials, weight gain or loss was not reported as a common or frequent side effect associated with Velsa.


Q: Is hair loss/skin rash a possible side effect of Velsa?

Official safety data indicates that rash has been reported as a less common side effect. Alopecia (hair loss) is also listed in reports collected after the medication was approved and made available to the public.


Q: Does Velsa interact with supplements like vitamins or herbal remedies?

The official prescribing information notes the importance of disclosing all concurrent medications, vitamins, and herbal supplements to a healthcare professional. This is a caution due to the potential for certain supplements to interact with Velsa, particularly those that affect potassium levels.


Q: How long do the effects of Velsa usually last?

According to pharmacokinetic studies, the blood pressure-lowering effect of a single dose of Velsa persists for a full 24 hours.


Q: Why is it important to take Velsa every day?

Velsa is prescribed for once-daily use to ensure the continuous blood pressure-lowering effect is maintained over a full 24-hour period. Consistent daily administration is necessary to achieve the maximum and sustained therapeutic benefit for chronic conditions like high blood pressure.


Q: Is Velsa a controlled substance?

No, Velsa is a prescription medication, but it is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major government drug scheduling authorities.


Q: Can Velsa be split or crushed?

Velsa is formulated as a film-coated tablet. Information regarding splitting or crushing should be sought from the prescribing professional or pharmacist.


Q: What should I do if Velsa makes me feel dizzy?

Dizziness is listed as a common side effect of Velsa. Official patient counseling information states that tasks requiring alertness, such as driving or operating heavy machinery, should be avoided if dizziness occurs. The product label indicates that severe dizziness or fainting warrants immediate contact with a healthcare professional.


Q: Does Velsa affect birth control pills or other hormonal medications?

Official regulatory documents do not list a direct drug-drug interaction between Velsa and hormonal contraceptives. However, if a patient experiences severe vomiting or diarrhea while taking Velsa, the efficacy of oral contraceptives may be affected, and additional guidance would be necessary.


Q: Is it normal to feel a bit sick when first taking Velsa?

The feeling of being 'a bit sick' may be associated with common side effects listed in the product information, such as nausea, abdominal pain, or diarrhea. These effects are generally expected to improve as your body adjusts to the medicine during the initial period of taking the medicine.


Q: Does Velsa work differently for men and women?

Official pharmacokinetic studies have been conducted to observe how the medicine is processed in the body. These studies determined that the way Velsa works, including its absorption and elimination, does not differ significantly between males and females.


Q: Can I stop taking Velsa if I feel better?

Velsa is a maintenance medication for chronic conditions. Because it is a maintenance medication for chronic conditions, discontinuation should only occur under the direction of a healthcare professional.


Q: Is Velsa a new medicine or has it been around for a while?

The active ingredient in Velsa (Valsartan) has been available for a significant period. It was first approved by the U.S. Food and Drug Administration (FDA) in 1997.


Q: Is there a generic version of Velsa available?

Yes, a generic version of the active ingredient in Velsa has been approved and is available for use. This information is typically confirmed through the FDA's generic approval records.


Q: Are there warnings about driving or operating machinery while taking Velsa?

Yes, official patient counseling information includes warnings about performing tasks that require mental alertness. Official patient counseling information notes that due to the potential for dizziness, tasks requiring mental alertness, such as driving or operating heavy machinery, should be approached with caution.


Q: Does Velsa have a black box warning in the US?

Yes, Velsa carries a Black Box Warning, which is the most serious warning required by the FDA. This warning specifically addresses the significant risk of fetal injury and death if the medication is taken during pregnancy.


Q: How is Velsa eliminated from the body?

Pharmacokinetic studies show that Velsa is primarily eliminated from the body via the feces (approximately 83% of the dose). A smaller amount is eliminated through the urine (approximately 13%), with most of the drug being eliminated unchanged.


Q: Can Velsa be used with blood thinners?

Official studies indicate there are no clinically significant interactions between Velsa and the blood thinner warfarin. Despite the lack of a significant clinical interaction with warfarin, the official label emphasizes the importance of disclosing all concurrent medications to the prescribing professional.


Q: Why is Velsa sometimes stopped before surgery?

Official guidelines exist regarding the management of this class of medication in the period leading up to elective surgery. The decision to temporarily interrupt the treatment is determined by the healthcare team to manage blood pressure risk during the procedure.

How should Velsa be stored and disposed of?

How to Store and Dispose of Velsa (Valsartan Tablets)

Velsa must be stored in accordance with official regulatory documentation to maintain product stability and safety.

Official Storage Conditions

Velsa tablets must be kept in the original container, which should be tightly closed. The medication must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). Storage is prohibited in environments where it may be exposed to excess heat, moisture, or freezing. The product must also be stored out of the sight and reach of children as a safety precaution.

Disposal Requirements

Any unused or expired Velsa must be disposed of according to local, regional, and national regulations. Official guidance states that unused medicine should not be discarded into the wastewater system, and patients are advised to consult a pharmacist for the proper disposal method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Velsa found in:

A-Z Index: